Mediflorence Medicaments Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 14 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth -14.61%
- Profit Growth 59.74%
- Ebitda 2.93%
- Net Worth 10.70%
- Total Assets 2.92%
About Mediflorence Medicaments
Mediflorence Medicaments Limited (MML) is a Public Limited Indian Non-Government Company incorporated in India on 09 February 2012 and has a history of 13 years. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.00 M.
Bijender Jain, Sunil Sharma, Nishant Agrawal, and One other member serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100DL2012PLC231292
- Company No.
231292
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Mediflorence Medicaments?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Sharma  | Director | 09-Feb-2012 | Current |
| Nishant Agrawal | Director | 30-Sep-2013 | Current |
| Bijender Jain | Director | 09-Feb-2012 | Current |
| Vibhu Sharma | Director | 15-Mar-2021 | Current |
Financial Performance of Mediflorence Medicaments.
Mediflorence Medicaments Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 14.61% decrease. The company also saw a substantial improvement in profitability, with a 59.74% increase in profit. The company's net worth Soared by an impressive increase of 10.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediflorence Medicaments?
In 2021, Mediflorence Medicaments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Integra Life Sciences Private LimitedBijender Jain is a mutual person
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Nov 2017 | Others | ₹2.00 M | Open |
How Many Employees Work at Mediflorence Medicaments?
Unlock and access historical data on people associated with Mediflorence Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediflorence Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediflorence Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
